Literature DB >> 8384936

Cell-signaling targets for antitumour drug development.

V G Brunton1, P Workman.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8384936     DOI： 10.1007/bf00685870

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  180 in total

Review 1.  Cellular and viral ligands that interact with the EGF receptor.

Authors:  G J Todaro; T M Rose; C E Spooner; M Shoyab; G D Plowman
Journal:  Semin Cancer Biol       Date:  1990-08       Impact factor: 15.707

Review 2.  The Raf-1 kinase as a transducer of mitogenic signals.

Authors:  D K Morrison
Journal:  Cancer Cells       Date:  1990-12

3.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

4.  [Leu13-psi(CH2NH)Leu14]bombesin is a specific bombesin receptor antagonist in Swiss 3T3 cells.

Authors:  P J Woll; D H Coy; E Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  1988-08-30       Impact factor: 3.575

Review 5.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

Review 6.  Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy.

Authors:  Y S Cho-Chung
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

7.  Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.

Authors:  A Gazit; N Osherov; I Posner; P Yaish; E Poradosu; C Gilon; A Levitzki
Journal:  J Med Chem       Date:  1991-06       Impact factor: 7.446

8.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

9.  Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases.

Authors:  M Hagiwara; S Inoue; T Tanaka; K Nunoki; M Ito; H Hidaka
Journal:  Biochem Pharmacol       Date:  1988-08-01       Impact factor: 5.858

10.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205
View more
  1 in total

1.  In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.

Authors:  H L McLeod; V G Brunton; N Eckardt; M J Lear; D J Robins; P Workman; M A Graham
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.